RNASEL and prostate cancer: Specifically, there was a significantly increased risk between prostate cancer and the RNASEL Asp541Glu polymorphism in ethnicity and source of cases, e.g. in the comparison of the Glu allele vs the Asp allele in African population (Fixed-effects OR = 1.13, 95% CI = 1.01-1.26, Pheterogeneity = 0.458), European population (Fixed-effects OR = 1.04, 95% CI = 1.01-1.07, Pheterogeneity = 0.828) and among studies with hospital-based prostate cancer cases (Fixed-effects OR = 1.06, 95% CI = 1.02-1.11, Pheterogeneity = 0.401).